GlassScriptPhysician profile
Francis Mcdermott
NPI 1437148491
$2,813.85
in general payments reported to CMS, 2019-2025
26 companies · $223 in 2025
The $223 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $750 · 2020: $172 · 2021: $307 · 2022: $940 · 2023: $104 · 2024: $318 · 2025: $223.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $644.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $644.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $471.86 | 2021-2025 | |
| Allergan, INC. | $404.18 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $371.18 | 2019-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $263.65 | 2021-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $214.38 | 2019-2024 | Invega Sustenna |
| Alkermes, INC. | $188.46 | 2019-2024 | Aristada, Lybalvi |
| Takeda Pharmaceuticals U.S.A., INC. | $120.97 | 2019-2025 | Trintellix |
| Merck Sharp & Dohme LLC | $102.57 | 2019-2022 | |
| Bausch Health US, LLC | $100.91 | 2022-2024 | Aplenzin |
| Axsome Therapeutics, INC. | $96.02 | 2024-2025 | Auvelity, Sunosi |
| Neurocrine Biosciences, INC. | $71.43 | 2019-2024 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $49.66 | 2021-2024 | Abilify Maintena, Rexulti |
| Supernus Pharmaceuticals, INC. | $45.57 | 2022 | |
| Almatica Pharma LLC | $43.90 | 2022-2024 | Loreev Xr |
| Corium, LLC | $42.57 | 2022-2023 | Azstarys |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $40.66 | 2019-2021 | |
| Idorsia Pharmaceuticals US INC | $36.49 | 2024 | Quviviq |
| Vanda Pharmaceuticals INC. | $36.01 | 2025 | Fanapt |
| Eisai INC. | $16.34 | 2021 | |
| Alfasigma USA, INC. | $15.86 | 2020 | |
| Azurity Pharmaceuticals, INC. | $15.12 | 2022 | |
| Avanir Pharmaceuticals, INC. | $14.26 | 2019 | |
| Mdd US Operations, LLC | $13.68 | 2019 | |
| Acadia Pharmaceuticals INC | $13.58 | 2019 | |
| Ironshore Pharmaceuticals INC. | $13.10 | 2021 | |
| Indivior INC. | $11.44 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Francis Mcdermott listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.